Recent Updates
Recently added Catalysts
LNTH Positive Sentiment

Lantheus Announces Share Repurchase Program

Key Takeaway: Lantheus Holdings, Inc. has announced a new share repurchase program authorized by its board of directors. The company plans to repurchase up to $250 million of its common stock over the next twelve months, showcasing confidence in its financial position and commitment to shareholder value. The repurchases are expected to commence in the fourth quarter and will be conducted based on market conditions and regulatory guidelines. Lantheus continues to focus on expanding its radiopharmaceutical portfolio while enhancing returns for shareholders.
Price reaction · baseline $79.43 (2024-11-19 close) · hit after-hours · clean, no other LNTH news in the window
day 0 close
+8.8%
day 1
+9.9%
day 3 · peak
+14.5%

Market Sentiment Analysis

POSITIVE FACTORS

  • Lantheus is initiating a $250 million share repurchase program, signaling strong financial confidence.
  • The program reflects the company's commitment to enhance shareholder value.
  • Lantheus aims to return capital to shareholders while pursuing business growth.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+48%
120-day peak, hindsight
Typical move
2%
average across 7 past catalysts
Lead asset
18F-DCFPyL
Phase 3 · Prostate Cancer

Full Press Release Details

Lantheus Announces Share Repurchase Program
BEDFORD, Mass., November 20, 2024 (GLOBE NEWSWIRE) Lantheus Holdings, Inc. (Lantheus or the Company) (NASDAQ: LNTH), the leading
radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver better patient outcomes, announces that its board of directors has authorized a program to repurchase up to $250 million of its
common stock during the next twelve months.
With our strong financial position and the Board s commitment to shareholder value, this share
repurchase program reflects our confidence in Lantheus continued radiopharmaceuticals leadership and ability to drive long-term, sustainable growth, said Brian Markison, Chief Executive Officer of Lantheus. We intend to commence
repurchases in the fourth quarter of this year and opportunistically return capital to shareholders over the next twelve months while simultaneously pursuing business development to expand our radiopharmaceutical portfolio.
Such repurchases may be made from time to time through open market transactions at prevailing market prices, in privately negotiated transactions, and through
other legally permissible means, depending on market conditions and in accordance with applicable rules and regulations. The actual timing, number, and dollar amount of repurchase transactions will be determined by the Company s management at
its discretion and will depend on a number of factors including, but not limited to, the market price of the Company s common stock. The Company may also establish 10b5-1 trading plans to provide
flexibility if and when it buys back its common stock.
Lantheus is the leading radiopharmaceutical-focused company, delivering life-changing science to enable clinicians to Find, Fight and Follow
disease to deliver better patient outcomes. Headquartered in Massachusetts with offices in Canada and Sweden, Lantheus has been providing radiopharmaceutical solutions for more than 65 years. For more information,
Safe Harbor for Forward-Looking and Cautionary Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, that are
subject to risks and uncertainties and are made pursuant to the safe harbor provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements
may be identified by their use of terms such as believe, continue, could, guidance, may, plan, potential, predict, progress,
should, target, will, would and other similar terms. These forward-looking statements include the Company s capital allocation plans, including the timing of any repurchases, and are subject to
the risks and uncertainties discussed in our filings with the Securities and Exchange Commission (including those described in the Risk Factors section in our Annual Reports on Form 10-K and our Quarterly
Reports on Form 10-Q).

Frequently Asked Questions

What is Lantheus' share repurchase program about?

Lantheus' board has authorized a $250 million share repurchase program over twelve months.

When will Lantheus start its stock repurchases?

Repurchases are scheduled to begin in the fourth quarter of this year.

How will the repurchases be conducted?

Repurchases may occur via open market transactions or privately negotiated deals.

What factors influence Lantheus' repurchase decisions?

Decisions will depend on market conditions, stock price, and management discretion.

How long has Lantheus been in the radiopharmaceutical field?

Lantheus has provided radiopharmaceutical solutions for over 65 years.

Last updated: Nov 20, 2024